Lumanity Reorganizes and Expands Strategic Consulting Capabilities
Lumanity Reorganizes and Expands Strategic Consulting Capabilities
Realigning global, clinical, regulatory, medical, and commercial consulting expertise to facilitate life science clients’ complex commercialization journey
Boston, MA., January 22, 2024 – Lumanity, a global strategic services partner, is realigning its strategic consulting capabilities to help clients more effectively create and demonstrate the value of assets throughout the development and commercialization lifecycle.
Lumanity acquired Clarion, a Boston-based life science consultancy, in October 2022. Clarion is now rebranding under Lumanity. In addition, Lumanity is realigning its Commercial, Medical Affairs, and Clinical and Regulatory Strategy teams into a single global Strategy Consulting capability.
Lumanity’s Strategy Consulting team helps clients identify and create value inflection points for their assets and organizations throughout the product lifecycle. These inflection points occur at critical investment and execution milestones that ultimately determine the success of a product in the marketplace. The creation of this new Strategy Consulting team best leverages Lumanity’s unique and diverse set of deeply experienced strategists, data luminaries, subject matter experts, and proven problem solvers.
“For our clients to navigate the journey from discovery to patient they must facilitate the alignment and exchange of expertise across a broad set of cross-functional experts,” said Jon Williams, the CEO of Lumanity. “When we bring unique combinations of our cross-functional experts together, we can partner with our clients to help bring their own teams closer together, resulting in better decision making and innovative, best-fit solutions with far greater impact.”
The Strategy Consulting team regularly draws on Lumanity’s broader capabilities and expertise in the areas of value demonstration, health economics and outcomes research (HEOR), market access, medical communications, insight, and real-world evidence to assemble and deploy solutions that support the strategic visions of client assets and help demonstrate the value created for all stakeholders.
“Successful value creation for today’s complex assets requires assessment of multiple indication choices, alternative development paths, asset profiles, and clearly defined data requirements often demanded by a broad and global set of clinical, payer, and patient stakeholders. By re-aligning our Strategy Consulting teams under common leadership, we are able to leverage the essential expertise to deliver powerful insights regarding how best to shape each asset and organization for success in the markets of tomorrow,” stated Tom Murtagh, co-founder of Clarion and Joint Global President of Strategy Consulting of Lumanity.
Lumanity’s Strategy Consulting team now consists of over 250 consultants based in the US, UK, and EU. For more information on Lumanity’s strategic consulting capabilities, visit its website.
ENDS
About Lumanity
Lumanity is a global strategic services partner built to effectively blend deep scientific, clinical, medical, regulatory, and commercial expertise to support complex client decision-making and execution throughout the asset value creation and demonstration journey. Lumanity powers successful commercialization and empowers patients, providers, payers, and regulators to take timely and decisive action to accelerate and optimize access to medical advances. With offices in North America, the United Kingdom, Europe, and Asia, and work conducted in over 50 countries, its 1,100+ experts work with nearly all the top pharmaceutical and more than 100 biotech companies around the world. Turning aspiration into reality, Lumanity supports over 50 payer submissions across 20+ countries, launch readiness and commercialization of 80 brands and new indications, and numerous award-winning product campaigns every year. For more information, please visit lumanity.com and connect with Lumanity on Twitter and LinkedIn
CONTACT for Lumanity:
Peter Marangos
+1 702 776 0985 / peter.marangos@lumanity.com
- 周子玄:新人小花深耕演技,穿搭时尚品味出众
- 张伟用老师受聘飞世界国际教育联盟美国访学专家顾问
- 济南正麦机械设备有限公司专业为河南客户生产啤酒设备
- 中信银行渭南分行助力区域经济高质发展
- 据说这是 死都不能让闺蜜先用的面膜“FILTERS滤镜之谜”面膜
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的?
- Laserfiche 渠道领导地位获得 2024 年 CRN®渠道领袖名单认可
- 直降3万击穿合资中型SUV基本盘,比亚迪护卫舰07荣耀版成新“卷王”
- 东莞宝盾精密机械有限公司——专业一站式定制专属精密机械
- 爱可声助听器邀您共赴第89届CMEF盛会!探索听力健康新纪元!
- 九亿科技多空矩阵量化系统:引领金融市场的智能交易新纪元
- 2024潮安智能卫浴产业大会将于本月下旬在潮州市举行
- TATA木门助力国乒健儿荣耀釜山,展现中国品牌力量
- 2024"庄周奖”长寿之道 中医春晚 暨全球文化科技大会
- Telegram营销软件采集隐藏成员,TG全自动群组采集软件,电报群成员采集利器
- 国家市场监督管理局解读《老人鞋》国标内容 足力健为第一起草单位
- View韩国面部轮廓手术案例:外轮廓才是拿捏颜值的关键!
- -40℃极寒漠河,海信红焰双高效系列硬核“通关”!
- 川渝风唱作人史宇翔献唱四川卫视农民工春晚主题曲
- 广州美博会今日开幕:35周年“开门红”,绽放美业新渠道机遇
- 中国公司拿下《机智的医生生活》独家版权 超一线班底预计6月开机
- 开启成功之门:NIQ的专家策略助力企业在2024年亚太地区消费市场中蓬勃发展
- 中奥物业捷和广场和颐澳湾花园荣获“2023年广东省住宅小区物业服务优秀示范项目”奖项
- 世界尚不知晓纳豆的功效:“Natto Power - 日本发酵食品纳豆,美好生活的关键”
- 曝光湖南省康宸新材料有限公司全屋整装感受景致风华涌入的瞬间
- 中国数字音乐基地发行成果显著 赵照《灯塔守望人》等作品备受瞩目
- 南京移动助力企业智改数转“加速度”
- 人生的多元选择-访全球引力移民总裁许莹
- 启航2024,广州大学城创业创新浪潮翻涌,集聚高质量发展澎湃力量
- 明牌珠宝——刘涛御钻珍华新形象,璀璨芳华,美韵人间
推荐
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯